The conversation discusses hair loss treatments, with the main focus on using Fluridil and considering switching to Pyrilutamide. Other treatments mentioned include minoxidil, topical finasteride, nizoral shampoo, and saw palmetto supplements, with advice to stick with Fluridil for at least six months before considering alternatives.
The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.
The conversation discusses hair regrowth using finasteride, minoxidil, ketoconazole shampoo (Nizoral), and microneedling as treatments. Users are sharing their experiences and results with these specific hair loss treatments.
Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.
A 19-year-old is concerned about going bald and disagrees with their parents who suggest therapy, believing hair loss will negatively impact their life. Some suggest therapy can help with the emotional aspects, while others support using finasteride and focusing on what makes the individual happy.
Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.
Microneedling can cause sneezing and eye tearing due to nerve stimulation, particularly near the temples and forehead. Some users find it lessens over time, while others prefer using finasteride and minoxidil for hair growth.
Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.
The user is considering adding low-level laser therapy (LLLT) to their hair loss treatment routine, which already includes minoxidil, finasteride, and microneedling. They are debating between purchasing a cheaper LLLT device or investing in a more expensive, clinically-backed option, with concerns about the effectiveness and specifications of cheaper models.
Hair loss discussion includes potential HMI-115 treatment. Topical mucuna pruriens shows good results, blocking prolactin possibly more important than blocking DHT.
The conversation is about making RU58841 solutions for hair loss treatment and sourcing ingredients for KB solutions. The user mentions using RU58841 powder from Shaanxi Greenyobiotech.
The user is hesitant to start a hair loss treatment regimen with Finasteride, Minoxidil, a derma stamp, and Nizoral shampoo due to concerns about potential side effects, despite being motivated by success stories. They seek advice from others who have faced similar dilemmas or have started treatment despite initial fears.
People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.
The conversation is about hair regrowth progress using a combination of treatments: dutasteride, minoxidil, RU58841, ketoconazole, and monthly microneedling. The user reports that microneedling and topical minoxidil had the most impact on their hairline.
Microneedling and Platelet-Rich Plasma (PRP) are equally effective for treating androgenetic alopecia, with no additional benefits from PRP over microneedling. Both treatments are safe and well-tolerated.
People are excited about a new hair loss treatment, PP405, and some suggest using Twitter to increase its visibility. Current treatments mentioned include finasteride, minoxidil, and dutasteride, but skepticism remains about the effectiveness of new treatments.
The conversation discusses hair regrowth progress using topical dutasteride with cetirizine, laser therapy, and growth serum. The user observes miniaturized, vellus hairs on the scalp.
Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.
A 48-year-old who had been thinning since 25 and reached NW4-5 baldness saw no improvement with 1mg/day finasteride and 5% minoxidil twice a day after 8 months. After copying another person's routine, they now use 0.5mg finasteride, ketoconazole shampoo weekly, daily microneedling with 0.5mm and 1mm once a week, and apply minoxidil twice daily, resulting in baby hairs on their bald spot and temples after three months.
The conversation discusses microneedling techniques and the use of Minoxidil, copper peptides, EGF, FGF, ceramides, and hydration serums to enhance hair growth. It explores optimizing scalp conditions and the potential benefits of various compounds in conjunction with microneedling.
The conversation is about managing allopregnanolone deficiency caused by 5-alpha-reductase inhibitors like finasteride or dutasteride. Specific treatments discussed for hair loss include Minoxidil, finasteride, and RU58841.
Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.
PP405 is progressing rapidly through trials, with mixed opinions on its potential effectiveness. Current treatments like minoxidil and finasteride are still widely discussed, with some users reporting positive results from new formulations.
A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.
A user shared their positive experience with Roots by GA, a company that creates personalized hair loss treatments based on DNA analysis, which confirmed their inability to tolerate finasteride. The user is satisfied with their progress 30 days after a hair transplant and the customized formula they received.
The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.
User experienced hair loss from Norwood 3.5 to Norwood 5 with diffuse thinning after using a hair system for 2 years. Tried Redensyl, Capixyl, Bicapil, Biotin, multivitamins, Fin, and Min without significant improvement, seeking advice for hair recovery.